Dapagliflozin improves glycemic control and reduces body weight as add-on therapy to metformin plus sulfonylurea: a 24-week randomized, double-blind clinical trial.
- DOI
- 10.2337/dc14-0666
- Published
- 2015 Mar
- Container
- Diabetes care
- Publisher
- Not recorded
- Open access
- no
Credibility signals
limited evidence Score 43/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- cautionDOI registered: No matching Crossref record was present in this response.
- cautionDOI resolves: No matching Crossref record was present in this response.
- not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredOpen access status: Not checked or no result supplied; no credibility inference made.
- not scoredPublication license: Not checked or no result supplied; no credibility inference made.
- not scoredPublication version: A publication version was supplied but is not scored.
- cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty.
Cite this work
BibTeX
@article{allodium:10.2337/dc14-0666,
title = {Dapagliflozin improves glycemic control and reduces body weight as add-on therapy to metformin plus sulfonylurea: a 24-week randomized, double-blind clinical trial.},
author = {Matthaei S and Bowering K and Rohwedder K and Grohl A and Parikh S and Study 05 Group},
year = {2015},
journal = {Diabetes care},
doi = {10.2337/dc14-0666},
url = {https://doi.org/10.2337/dc14-0666}
}RIS
TY - JOUR TI - Dapagliflozin improves glycemic control and reduces body weight as add-on therapy to metformin plus sulfonylurea: a 24-week randomized, double-blind clinical trial. AU - Matthaei S AU - Bowering K AU - Rohwedder K AU - Grohl A AU - Parikh S AU - Study 05 Group PY - 2015 JO - Diabetes care DO - 10.2337/dc14-0666 UR - https://doi.org/10.2337/dc14-0666 ER -
APA
S, M., K, B., K, R., A, G., S, P., & Group, S. 0. (2015). Dapagliflozin improves glycemic control and reduces body weight as add-on therapy to metformin plus sulfonylurea: a 24-week randomized, double-blind clinical trial.. Diabetes care. https://doi.org/10.2337/dc14-0666
Source records
- pubmed · retrieved 2026-09-26T23:56:49.574Z
- europe-pmc · retrieved 2026-09-26T23:56:49.591Z